Myalgia - Fibromyalgia

 

Chapter 11Myalgia and Fatigue

Translation from Mouse Sensory Neurons to Fibromyalgia and Chronic Fatigue Syndromes

Alan R. Light, Charles J. Vierck, and Kathleen C. Light.

https://www.ncbi.nlm.nih.gov/books/NBK57253/

Erectile Dysfunction Problem

It is not be neglected. It can be the early symptom of cardiovascular problems. There is need to consult doctor and do the treatment as prescribed.

Experts now believe that erectile dysfunction preceding heart problems is more often due to the dysfunction of the inner lining of the blood vessels (endothelium) and smooth muscle. Endothelial dysfunction causes inadequate and impaired blood flow to the penis leading to ED. It also results in   inadequate blood supply to the heart and it aids in the development of atherosclerosis, which is buildup of plaque.

https://www.mayoclinic.org/diseases-conditions/erectile-dysfunction/in-depth/erectile-dysfunction/art-20045141

Free Access

Endothelial Dysfunction in Erectile Dysfunction: Role of the Endothelium in Erectile Physiology and Disease

Trinity J. Bivalacqua, Mustafa F. Usta, Hunter C. Champion, Philip J. Kadowitz, Wayne J. G. Hellstrom

First published: 02 January 2013 https://doi.org/10.1002/j.1939-4640.2003.tb02743.x

https://onlinelibrary.wiley.com/doi/10.1002/j.1939-4640.2003.tb02743.x

The corpus cavernosum of the penis is composed of a meshwork of interconnected smooth muscle cells lined by vascular endothelium. Of note, endothelial cells and underlying smooth muscle also line the small resistance helicine arteries that supply blood to the corpus cavernosum during penile tumescence. Pathological alteration in the anatomy of the penile vasculature or impairment of any combination of neurovascular processes can result in ED.

https://my.clevelandclinic.org/health/body/23471-endothelium

Blood Vessels and Endothelial Cells

https://www.ncbi.nlm.nih.gov/books/NBK26848/

Tadalafil in the treatment of erectile dysfunction

PDE5 Inhibitors

Armaan Dhaliwal; Mohit Gupta.

Last Update: April 10, 2023.

https://www.ncbi.nlm.nih.gov/books/NBK549843/

Tadalafil in the treatment of erectile dysfunction

Robert M Coward and Culley C Carson

Ther Clin Risk Manag. 2008 Dec; 4(6): 1315–1330.

Published online 2008 Dec. doi: 10.2147/tcrm.s3336

PMCID: PMC2643112

PMID: 19337438

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643112/

Originally Published 28 August 2006

Free Access

Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension

James J. Oliver, Vanessa P. Melville, and David J. Webb

https://www.ahajournals.org/doi/full/10.1161/01.HYP.0000239816.13007.c9

Adverse Effects

25 persons were in the study

Two subjects were withdrawn while taking sildenafil, 1 because of severe headache (after 3 days) and the other because of back pain and feeling generally unwell (after 6 days), and 1 subject was withdrawn while taking placebo, because of joint pains, nausea, and headache (after 11 days). For a full summary of the symptoms experienced see the online supplement. Dyspepsia occurred in 10 subjects with sildenafil and lasted ≤5 days. Headaches occurred in 8 subjects and were generally mild and transient. Low back/buttock/leg muscle ache occurred in 7 subjects, was usually responsive to simple analgesia, and tended to settle within a few days. Plasma creatine kinase concentrations were measured in 4 of the subjects who experienced these symptoms, and all were within the normal laboratory reference range. Six of the 18 men in the study reported increased penile erection, which occurred only with sildenafil.

Ud. 12.6.2024

Pub. 30.4.2023

Chronic Kidney Disease - Tests and Treatment Information

https://www.mayoclinic.org/diseases-conditions/chronic-kidney-disease/symptoms-causes/syc-20354521

https://my.clevelandclinic.org/health/diseases/15096-chronic-kidney-disease

https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd

https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd

Diagnosis and Management of Chronic Kidney Disease
November 2008

Chronic kidney disease (CKD), is  defined by a reduction in the estimated glomerular filtration rate (GFR). It is increasing because of the greater prevalence of obesity and hypertension but in greater part because of improved longevity. Because GFR declines 1% per year for every year of life after the third decade, living longer means that it is possible to outlive one’s renal function and to require renal replacement therapy to stay alive. Longevity increases the risk of developing diseases, such as diabetes, hypertension, and atherosclerotic vascular disease, that have direct adverse effects on kidney function.

http://www.mayomedicallaboratories.com/articles/communique/2008/11.html

Ud. 29.8.2024

Pub 30.12.2016

Excess Salt May Make Arteries Stiff and Cause Vascular Problems

Data from both animal and human studies provide evidence that salt impairs endothelial function and increases arterial stiffness independent of blood pressure.
Vascular Effects of Dietary Salt
David G. Edwards and William B. Farquhar
Curr Opin Nephrol Hypertens. Author manuscript; available in PMC 2017 May 15.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431073/

Heart failure and salt: The great debate

December 18, 2018

https://www.health.harvard.edu/blog/heart-failure-and-salt-the-great-debate-2018121815563

Vascular Stiffness in Aging and Disease

REVIEW article

Front. Physiol., 07 December 2021

Sec. Vascular Physiology

https://doi.org/10.3389/fphys.2021.762437

This article is part of the Research Topic

Cardiovascular Remodeling in Aging and Disease

https://www.frontiersin.org/articles/10.3389/fphys.2021.762437/full

Effects of Sodium Intake on Health and Performance in Endurance and Ultra-Endurance Sports

by Eleftherios Veniamakis 1,Georgios Kaplanis 1,Panagiotis Voulgaris 1 andPantelis T. Nikolaidis 2,*ORCID

1

Department of Nutrition and Dietetics, Hellenic Mediterranean University, 72300 Sitia, Greece

2

School of Health and Caring Sciences, University of West Attica, 12243 Athens, Greece

*

Author to whom correspondence should be addressed.

Academic Editor: Alberto Pérez-López

Int. J. Environ. Res. Public Health 2022, 19(6), 3651; https://doi.org/10.3390/ijerph19063651

Received: 26 January 2022 / Revised: 3 March 2022 / Accepted: 8 March 2022 / Published: 19 March 2022

https://www.mdpi.com/1660-4601/19/6/3651/htm

Dietary Sodium Restriction Reverses Vascular Endothelial Dysfunction in Middle-Aged/Older Adults With Moderately Elevated Systolic Blood Pressure

FREE ACCESS

Hypertension

Kristen L. Jablonski, Matthew L. Racine, Candace J. Geolfos, Phillip E. Gates, Michel Chonchol, Matthew B. McQueen, and Douglas R. Seals

J Am Coll Cardiol. 2013 Jan, 61 (3) 335–343

Clinical significance

The concept that high sodium intake has adverse CV effects independent of BP has been advanced previously (9,12). High dietary sodium impairs EDD even in rodents that are salt-resistant and, thus, do not exhibit increases in BP in response to a high-salt diet (13,18,20). Acute impairment of EDD in normotensive adults after sodium loading also is BP independent (11), and adults with elevated SBP who report lower sodium intake have enhanced EDD independent of BP (16). The present results extend these findings to sodium restriction and lend support to the overall hypothesis that sodium intake not only elevates BP but also exerts other adverse influences (12). The effects of sodium restriction on endothelial function reported here also complement previous findings that reducing sodium intake can rapidly de-stiffen large elastic arteries (21), another independent vascular risk factor for CVD (40). The improvements in these 2 common forms of arterial dysfunction, both predictors of CV events (3,4,40), suggest that DSR has strong potential for reducing CVD risk via broad vasculoprotective effects.

https://www.jacc.org/doi/10.1016/j.jacc.2012.09.010

ud. 12.6.2024,   24.9.2022, 17.9.2022

pub. 25.9.2019

23 BMI - Risk Factor for Cardiovascular Problems for Indians and Asians - Don't Allow Your Weight to Increase and Cross 23 BMI

 

BMI above 23 is a risk factor for cardiovascular and metabolic disorders. Please note. Do not allow weight to increase and cross 23 BMI.

Diabetes is metabolic disorder. Triglycerides and Cholesterol are also metabolic disorders and have the foundation in food habits causing diabetes.

Increase in blood pressure indicates that a permanent problem in blood flow occurred in the blood pipes or vessels. When the problem occurs in main arteries, various pain symptoms appear. When the problem is in minor arteries, only blood pressure is the visible measurement.

Discussion Regarding 23 BMI

It is clear that increased body weight is a risk factor for type 2 diabetes. The relationship between body weight and type 2 diabetes is more properly attributable to the quantity and distribution of body fat . Abdominal circumference and waist and hip measurements are highly correlated with cardiometabolic risk.

The measurement of body weight with various corrections for height is frequently used to assess risk for obesity-related diseases because it is the most economical and practical approach in both clinical and epidemiologic settings. The most commonly used measure is Quetelet’s index or BMI, defined as weight ÷ height2, with weight in kilograms and height in meters. 

There is a propensity for Asians to develop visceral versus peripheral adiposity, which is more closely associated with insulin resistance and type 2 diabetes than overall adiposity.  Asians of both sexes have been shown to have a higher percentage of body fat at any given BMI level compared with non-Hispanic whites; this suggests differences in body composition that may contribute to variations in diabetes prevalence.

In 2004, data from the Behavioral Risk Factor Surveillance System (BRFSS) showed that the odds of prevalent diabetes were 60% higher for Asian Americans than non-Hispanic whites after adjusting for BMI, age, and sex (23). The National Health Interview Survey (NHIS; 1997–2008 data)  found that the odds of prevalent diabetes were 40% higher in Asian Americans relative to non-Hispanic whites after adjusting for differences in age and sex. In fully adjusted logistic regression models including an adjustment for BMI as a categorical variable (underweight/normal weight: BMI <23 kg/m2, overweight: 23 ≤ BMI < 27.5 kg/m2, and obese: BMI ≥27.5 kg/m2), Asian Americans remained 30–50% more likely to have diabetes than their non-Hispanic white counterparts.

Thus in the Diabetes Prevention Program (DPP), a BMI value of 22 kg/m2 was selected as the eligibility BMI for Asians. 

 The diagnostic cutoff for overweight BMI in India (48) is 23 kg/m2.

BMI cut points with a sensitivity of 80% fall consistently between 23–24 kg/m2 for nearly all Asian American subgroups (with levels slightly lower for Japanese). This makes a rounded cut point of 23 kg/m2 practical

ADA Recommendation

Testing for diabetes should be considered for all Asian American adults who present with a BMI of ≥23 kg/m2.

https://diabetesjournals.org/care/article/38/1/150/37769/BMI-Cut-Points-to-Identify-At-Risk-Asian-Americans

48.Misra A, Chowbey P, Makkar BM, et alConcensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163–170

[PDF] researchgate.net

[PDF] Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity …

A Misra, P Chowbey, BM Makkar, NK Vikram, JS Wasir… - Japi, 2009 - researchgate.net

Asian Indians exhibit unique features of obesity; excess body fat, abdominal adiposity,

increased subcutaneous and intra-abdominal fat, and deposition of fat in ectopic sites (liver,

muscle, etc.). Obesity is a major driver for the widely prevalent metabolic syndrome and type

2 diabetes mellitus (T2DM) in Asian Indians in India and those residing in other countries.

Based on percentage body fat and morbidity data, limits of normal BMI are narrower and

lower in Asian Indians than in white Caucasians. In this consensus statement, we present …

https://www.researchgate.net/profile/Janaki-Srinath-Puskuri/publication/325404564_Consensus_Statement_for_Diagnosis_of_Obesity_Abdominal_Obesity_and_the_Metabolic_Syndrome_for_Asian_Indians_and_Recommendations_for_Physical_Activity_Medical_and_Surgical_Management/links/5b0c416a0f7e9b1ed7fbabc2/Consensus-Statement-for-Diagnosis-of-Obesity-Abdominal-Obesity-and-the-Metabolic-Syndrome-for-Asian-Indians-and-Recommendations-for-Physical-Activity-Medical-and-Surgical-Management.pdf

 

48.Misra A, Chowbey P, Makkar BM, et alConcensus Group. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163–170

https://diabetesjournals.org/care/article/38/1/150/37769/BMI-Cut-Points-to-Identify-At-Risk-Asian-Americans

[PDF] researchgate.net

[PDF] Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity …

A Misra, P Chowbey, BM Makkar, NK Vikram, JS Wasir… - Japi, 2009 - researchgate.net

Asian Indians exhibit unique features of obesity; excess body fat, abdominal adiposity,

increased subcutaneous and intra-abdominal fat, and deposition of fat in ectopic sites (liver,

muscle, etc.). Obesity is a major driver for the widely prevalent metabolic syndrome and type

2 diabetes mellitus (T2DM) in Asian Indians in India and those residing in other countries.

Based on percentage body fat and morbidity data, limits of normal BMI are narrower and

lower in Asian Indians than in white Caucasians. In this consensus statement, we present …

https://www.researchgate.net/profile/Janaki-Srinath-Puskuri/publication/325404564_Consensus_Statement_for_Diagnosis_of_Obesity_Abdominal_Obesity_and_the_Metabolic_Syndrome_for_Asian_Indians_and_Recommendations_for_Physical_Activity_Medical_and_Surgical_Management/links/5b0c416a0f7e9b1ed7fbabc2/Consensus-Statement-for-Diagnosis-of-Obesity-Abdominal-Obesity-and-the-Metabolic-Syndrome-for-Asian-Indians-and-Recommendations-for-Physical-Activity-Medical-and-Surgical-Management.pdf

Nitric Oxide - Enabler of Cardio Vascular Health

New insights into nitric oxide in congestive heart failure make "the next step" possible
Shelley Wood
April 23, 2004
http://www.medscape.com/viewarticle/784684


What Are the Benefits of Nitric Oxide Supplements?
by KRISTEN UNGER  Last Updated: Aug 25, 2014
http://www.livestrong.com/article/518715-the-supplements-and-foods-that-increase-nitric-oxide-production/

Nitric oxide for heart health

WHAT is Nitric Oxide?  Discovery
http://www.all-fitness.info/2015/10/nitric-oxide-for-heart-health.html

Endothelial Health!
Posted on November 14, 2011
http://no-more-heart-disease.com/



A SIGNAL FOR A HEALTHY HEART
http://www.doctor-recommended.com/blog/a-signal-for-a-healthy-heart/

Foods That Contain L-Arginine, L-Citrulline, And Folic Acid

Daniel Hammer
http://www.danhammerhealth.com/
______________________

______________________

Ud. 12.6.2024

Pub. 5.11.2016

Redesign Dental Clinics - Hyderabad - for Smile and Comfort - Dental Treatment in a Friendly Environment

 

https://redesigndentalclinics.com/

PCOD - PCOS - Diet and Treatment Related Information

2023

Open access

Published: 16 January 2023

Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity

Stephanie Cowan et al.

BMC Endocrine Disorders volume 23, Article number: 14 (2023) 

https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-01208-y

Nutrients. 2021 Jul; 13(7): 2452.

Published online 2021 Jul 18. doi: 10.3390/nu13072452

PMCID: PMC8308732

PMID: 34371961

Nutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review

Małgorzata Szczuko,1,*

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308732/

BRIEF RESEARCH REPORT article

Front. Nutr., 04 April 2022

Sec. Food Chemistry

Volume 9 - 2022 | https://doi.org/10.3389/fnut.2022.876620

Mediterranean Diet Combined With a Low-Carbohydrate Dietary Pattern in the Treatment of Overweight Polycystic Ovary Syndrome Patients

Shanshan Mei1,2†

I like the breakup of calories.

https://www.frontiersin.org/articles/10.3389/fnut.2022.876620/full

Mediterranean Diet Suggestions

https://www.eatingwell.com/article/7763980/mediterranean-diet-plan-for-beginners/

https://www.eatingwell.com/article/2058271/vegan-mediterranean-diet-plan/

PCOS and Depression

Polycystic Ovarian Syndrome–Related Depression in Adolescent Girls: A Review

Saleha Sadeeqa, Tehreem Mustafa, and Sumaira Latif

J Pharm Bioallied Sci. 2018 Apr-Jun; 10(2): 55–59.  doi: 10.4103/JPBS.JPBS_1_18

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998697/

Care Hospitals - PCOD Diet Chart: Foods to Eat and Avoid

Updated on 30 October 2023

https://www.carehospitals.com/blog-detail/pcod-diet-foods-to-eat-and-avoid/

Therapeutic Fasting - Dr Jason Fung

Treatment Option for PCOS

___________________

___________________



Lost 17 pounds in 21 days with PCOS
___________________


___________________



Fasting and Polycystic diseases
Dr. Jason Fung
Nephrologist. Special interest in weight management and diabetes
Aug 9, 2017
https://medium.com/@drjasonfung/much-new-and-interesting-data-support-the-benefits-of-fasting-in-diseases-other-than-obesity-and-868a73734a63


Dr. Jason Fung's Web site
https://idmprogram.com/blog/

Samantha – Polycystic Ovary Patient Profile
https://idmprogram.com/samantha-polycystic-ovary-patient-profile/

Dr. Jason Fung -  IDM Program -  Online Consultation is available for PCOS related Dieting.

https://www.dietdoctor.com/authors/dr-jason-fung-m-d



Regular Allopathic Treatment Information

Polycystic ovary syndrome (PCOS)
Mayo Clinic
https://www.mayoclinic.org/diseases-conditions/pcos/diagnosis-treatment/drc-20353443

Polycystic Ovary Syndrome (PCOS) - Treatment Overview
WebMD
https://www.webmd.com/women/tc/polycystic-ovary-syndrome-pcos-treatment-overview


https://www.womenshealth.gov/a-z-topics/polycystic-ovary-syndrome


IS THERE A CURE FOR PCOS?
PCOS AWARENESS ASSOCIATION IS REGISTERED AS A 501(C)(3) NON-PROFIT ORGANIZATION.
CONTRIBUTIONS TO PCOS AWARENESS ASSOCIATION ARE TAX-DEDUCTIBLE TO THE EXTENT PERMITTED BY LAW.
PCOS AWARENESS ASSOCIATION'S TAX IDENTIFICATION NUMBER IS EIN #46-1182190.
http://www.pcosaa.org/is-there-a-cure-for-pcos/


https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/treatment/

Ud. 12.1.2023,  12.12.2023

Pub. 4.2.2018

Super Ageing Challenge - Research, Policies, and Programs

Super-aging Society.

Engage all generations in discussions

on how to confront the super-aging society.

The challenges of a super-aging society cannot be solved only by direct approaches to the problems faced by the elderly. Efforts to improve the quality of life of all generations and the social and economic innovations that support them are essential. It is also essential to take perspectives such as addressing the declining birthrate.

This conference will identify the changes and challenges that a super-aging society will bring to the world, and discuss the path to solutions from the perspective of all generations, not just the elderly.

https://www.global-nikkei.com/ifsa/23/en/

Life time health care - medical checkups

75 years check-up

Eric Verdin

President and CEO,

Buck Institute for Research on Aging

Interesting presentation

https://www.linkedin.com/in/eric-verdin-490212/

https://nam.edu/wp-content/uploads/2021/06/Eric-Verdin-Powerpoint-Presentation.pdf

https://en.wikipedia.org/wiki/Buck_Institute_for_Research_on_Aging

https://www.timelinenutrition.com/blog/we-re-on-the-verge-of-changing-how-we-will-age-dr-verdin

Want to live healthier longer? Scientists aim to improve life quality over quantity

Karen Weintraub

USA TODAY

10 July 2023

Everyone's different, of course, and people will have different needs at different stages of life. A professional football player needs a lot more protein than the average person. But after retirement, if that player eats the same amount of protein while exercising far less, it will lead to unhealthy fat, she said.

With as many as 50 clinical trials underway around the world, he thinks it won't take too long to figure out whether existing drugs can be repurposed to reduce the severity of some of the worst diseases of aging, such as advanced Alzheimer's and some cancers.

https://www.usatoday.com/story/news/health/2023/07/10/longevity-rapamycin-metformin-life-span-aging-research/70392701007/

World's oldest person, French nun Sister André, dies aged 118

Published

18 January 2023

https://www.bbc.com/news/world-europe-64314673

Integrated Care for Older People - WHO  ICOPE  (Dr. Srimannarayana)

Linda P. Fried

Dean, Columbia University’s Mailman School of Public Health

Director, Robert N Butler Columbia Aging Center

Linda Fried

A geriatrician and epidemiologist, Dr. Fried has dedicated her career to the science of healthy aging, particularly the science of prevention of frailty, disability, and cardiovascular disease. She has led the scientific discoveries as to the definition, biology and causes of the syndrome of frailty. Dr. Fried has proposed that the creation of healthy longevity and new societal institutions that enable older adults could transform the potential of our longer lives into a Third Demographic Dividend where all ages and societies flourish. Under her leadership as dean, Columbia Mailman has developed new dimensions of public health science from the health impacts of climate change to healthy longevity, and has become a key leader in innovation in public health education. Prior to becoming Dean in 2008, she was the Director of Geriatric Medicine and Gerontology and of the Center on Aging and Health at the Johns Hopkins Medical Institutions. Dr. Fried is the recipient of numerous honors and awards, including the French INSERM International Prize in Medical Research in 2017. President of the Association of American Physicians in 2016-2017, she was the recipient of their Kober Medal in 2022. She serves on the National Academy of Medicine’s Executive Council and recently co-chaired its Global Commission on a Global Roadmap for Healthy Longevity.

Vision 2050 Health Longevity World - NAM, USA

Health span to match life span

Preventions Required

Non communicable chronic diseases

Fraility

Falls

Cognitive decline and dementia

Loneliness

Presentations by her are to be found and downloaded

Volunteering by old persons contributes to their health.

Akiko Kishi Svensson

Project Assistant Professor,

Precision Health, Department of Bioengineering, Graduate School of Engineering,

The University of Tokyo

AkikoKishi

M.D., Ph.D, (Internal Medicine), MSc ( Public Health Nutrition)

After obtaining Japan Diabetes Society specialist license, she has been supporting clinical researchers and innovation as a project assistant professor at the Clinical Research Support Center, the University of Tokyo Hospital.

Since 2016, she has focused on metabolic syndrome, a gateway to lifestyle-related diseases, and launched the "Body projection" project to promote the personalization of health through the risk prediction and visualization of health information, and developed an app and health management system that leads to behavioral change.

Since 2018, she has her current position at the Graduate School of Engineering, and from 2021 she is CMO of the University of Tokyo venture company Medmirai, Inc.

Currently, based on her experience in home medical care and in the engineering field, she is the Principal Investigator for the unique healthy ageing cohort study which aim to predict and personalize information on healthy longevity through deep learning and multi-omics. This study is ongoing study which investigates detailed biological data and digital data obtained from wearable devices and apps from healthy Japanese who is over 80 years old.

She is also an organizing committee member for the 18th Key Symposium of the Journal of Internal Medicine and the Royal Swedish Academy of Sciences "Longevity and healthy ageing” which took place on May 2023 in Okinawa.

Reducing risk factors for clinical diseases

Health is a creator of value - Very important point.

2nd Day

Asia's Future in the Face of Dramatic Demographic Shifts and Their Impact on Healthcare

John R. Beard

Irene Diamond Professor and Director, International Longevity Center - USA, Columbia University, New York

John Beard, MBBS PhD, is Irene Diamond Professor and Director of the International Longevity Center-USA at Columbia University, New York. He was previously Director of Ageing and Life Course with the World Health Organization in Geneva.

While at WHO, he led development of the World report on ageing and health which underpins the current UN Decade of Healthy Ageing, and was responsible for many global initiatives including development of the Integrated Care for Older People (ICOPE) programme, and the Global Network of Age-friendly Cities and Communities which current covers over 300 million people. He has worked extensively with the World Economic Forum and participated in the recent US National Academy of Medicine Commission on Healthy Longevity.

Embracing the Poulation Aging: Exploring the Far-Reaching Effects and Business Opportunities

NobuyukiKii

Nobuyuki Kii

Group Manager,

Research & Consulting Division

Aging Innovation Group

The Japan Research Institute,Limited

Socks

Prepaid cards for payment

Gas stoves redesigned to help

Product Innovations to support persons with dementia

Nursing Care Technologies

AgeTech Equipment

ERIA Grouping

ASEAN plus 6 East Asian Countries - India is there.

Health Care Unit of ERIA.

Active Ageing

https://www.global-nikkei.com/ifsa/22/en/

https://ps.nikkei.com/ifsac2021/

Japan's ageing society

Briefing 15-12-2020

Share this page on Facebook

Share this page on Twitter

Share this page on LinkedIn

Japan is aging fast. Its 'super-aged' society is the oldest in the world: 28.7 % of the population are 65 or older, with women forming the majority. The country is also home to a record 80 000 centenarians. By 2036, people aged 65 and over will represent a third of the population. Since 2011, the Japanese population has also been shrinking: it is a rare case of large country whose overall population is becoming smaller in prosperous and peaceful times. Japan's population is expected to drop from 127 million in 2015 to 88 million by 2065. Japan's demographic crisis is the consequence of the combination of two elements: a high life expectancy and a low fertility rate. In 2018, Japan had the second highest life expectancy in the world. Meanwhile, since the 1970s the country has failed to raise its fertility rate to the replacement level. The working culture, a deterioration of employment opportunities for young men and the traditional gender division of labour are possible explanations for this trend. The consequences of the country's aging and shrinking population include economic crisis, budgetary challenges, pressure on job markets and depopulation of rural areas. The silver economy is meanwhile flourishing and Japan is at the forefront of robot development to face a declining labour force and to take care of its elderly. The government's efforts to address the demographic crisis have yet to succeed however, and immigration has been limited. Tokyo is engaged in global health cooperation and succeeded in incorporating the concept of human security in the sustainable development goals. It has also been active in international cooperation on ageing, with a focus on the Association of Southeast Asian Nations (ASEAN) region. The EU's own ageing society is not far behind Japan. It could benefit from learning from Japan's experience, and cooperating on all aspects relating to demographic challenges, including on 'agetech': technology making comfortable longevity accessible to all.

You can download full document

https://www.europarl.europa.eu/thinktank/en/document/EPRS_BRI(2020)659419

Ageing Society

In this report, we qualify a country as “ageing society” if the share of people aged 65 years or more is between 7% and 14 of the total population, as “aged society” if this share is between 15% and 20% and as “super-aged society” if this share is 21% or higher.

https://www.oecd-ilibrary.org/sites/1ad1c42a-en/index.html?itemId=/content/component/1ad1c42a-en

Spending 2000 Calories per Day - Experience and Plan

21.8.2023

Found it difficult to spend 2000  calories. Now I am reducing the target to 1650 calories in Google Fit due to default calories consumption and additional steps.  100 calories may be consumed extra due to exercises and routine activities. So plan to eat  close to 1750 calories and do intermediate fasting and morning walk. Intermediate fasting 14 to 16 hour break. Morning walk 50 to 60 minutes. Today morning weight is 62.5 kg. Let me see after a month the results. I can always reduce the calories once again and increase walking if required later.

9.6.2023

Last month, I downloaded and installed Google Fit App.

It gives a figure of calories consumed.

Only on yesterday 8 June 2023, I could see the figure above 2000 calories.

2090 calories consumed. 15183 steps. 9.39 km walked. active 282 minutes.

Up to 10 am, walked within the house 6500 steps.

After 10 am went out and walked for 30 minutes. Completed 9600 steps before 11 am.

1000 calories were consumed by 11 am.

9 June 2023

Calories consumed 1966

Steps - 15016

Spending 2000 calories is not easy. But on some more days I did record 2000 calories.

20th June 2066  20,212 steps  3 hrs 21 minutes

22            2019   15,020  2 hrs 54 mts

23            2016    15,018   3 hrs 11 minutes

ud. 21.8.2023, 30.6.2023

Pub 9.6.2023

Outer Ankle Edema

 

https://www.florhamparkpodiatry.com/blog/item/104-why-is-the-outside-of-my-ankle-swollen.html

https://www.sportsinjuryclinic.net/sport-injuries/ankle-pain/lateral-ankle-pain

https://www.medic8.com/healthguide/blood-pressure/swollen-ankles.html

Peronial Tendinopathy

https://www.nhslanarkshire.scot.nhs.uk/services/physiotherapy-msk/peroneal-tendinopathy/

Peroneal Tendonitis

https://my.clevelandclinic.org/health/diseases/22003-peroneal-tendonitis

Case Report | Open Access

Volume 2018 | Article ID 1215653 | https://doi.org/10.1155/2018/1215653

Show citation

When Should a Patient with Statin-Induced Myopathy Be Re-challenged? A Case of Necrotizing Autoimmune Myopathy

Elena Obreja

,1Pamela Sequeira,2and Diana Girnita

3

https://www.hindawi.com/journals/crirh/2018/1215653/

Ud. 14.8.2023

Pub. 5.5.2023

Vitamin D - Deficiency Signs - Required Quantity and Ways

Vitamin D Deficiency Signs

1. Chronic fatigue and tiredness

2. Struggling with depression

3. Loss of bone density

4. Experiencing loss of hair

5. Frequent illness and infection

6. Slow wound healing

7. Gut issues like IBS 

Vitamin D deficiency has been associated with inflammatory diseases including inflammatory bowel disease (IBD).

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566188/

8. Unexplained joint and back pain

9. Weight gain

Having inadequate levels of vitamin D may correlate with unintentional weight gain. A study on women over the age of 65 found that participants with a lower vitamin D level experienced more weight gain.

https://www.everlywell.com/blog/vitamin-d/vitamin-d-deficiency-and-weight-gain/

https://www.ndtv.com/health/vitamin-d-deficiency-know-common-signs-and-symptoms-and-tips-to-deal-with-it-4075422

Daily 2000 IUs inadequate as maintenance dose.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135651/


Take vitamin D along with high fat diet.

Up to 4000 IU daily is safe.
https://www.healthline.com/nutrition/vitamin-d-dosage#section1


2009
https://www.sciencedaily.com/releases/2009/10/091026161850.htm

Ud. 1.6.2023

Pub. 30.5.2020

Hypertension - Blood Pressure

GLOBAL BURDEN OF HYPERTENSION

Based on an analysis of data from 135 population-based studies that included 968,419 adults from 90 countries, we estimated that in 2010 the global age-standardized prevalence of hypertension (defined as systolic BP ≥140 mm Hg, diastolic BP ≥90 mm Hg, and/or current use of antihypertensive medication) was 31.1% (95% CI 30.0–32.2%).

Estimates suggest that in 2010, 31.1% of adults (1.39 billion) worldwide had hypertension. The prevalence of hypertension among adults was higher in LMICs (31.5%, 1.04 billion people) than in high-income countries (HICs; 28.5%, 349 million people). Variations in the levels of risk factors for hypertension, such as high sodium intake, low potassium intake, obesity, alcohol consumption, physical inactivity and unhealthy diet, may explain some of the regional heterogeneity in hypertension prevalence

In 2017, the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines redefined hypertension in adults as systolic BP ≥130 mmHg and/or diastolic BP ≥80 mmHg. This change was based on findings from a number of large-scale, prospective observational studies that reported significant increases in risk of CVD with increasing BP even from levels as low as systolic BP 115 mmHg, as well as the results of randomized clinical trials including the SPRINT trial (discussed further below) that showed that intensive BP lowering (target systolic BP <120 mmHg) reduces CVD and all-cause mortality to an even greater extent than does standard BP lowering (target systolic BP ≤140 mmHg). When the new definition was applied to the US general population, hypertension prevalence increased from 32.0% (based on the traditional criteria) to 45.4% (Table 2).19,20 In the Chinese general population, the increase was even greater from 23.2% to 46.4%.19,20 These findings suggest that if the new criteria were applied worldwide, the difference in hypertension prevalence between LMICs and HICs would be much greater than previously reported.3 Full implementation of the new guidelines would require a greater proportion of adults to be treated with antihypertensive medications but could prevent an estimated 610,000 CVD events and 334,000 deaths per year in the US alone.19

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998524/

WHO on Hypertension 

https://www.who.int/news-room/fact-sheets/detail/hypertension

Cilnidipine and Telmisartan Similarly Improves Vascular Damage in Hypertensive Patients

Yuki Kaneshiro, Atsuhiro Ichihara, M.D., Ph.D., FAHA, Mariyo Sakoda, ...

First Published January 1, 2007 Research Article

https://doi.org/10.4137/CMC.S353

https://journals.sagepub.com/doi/full/10.4137/CMC.S353

Ud. 30.5.2023

Pub. 12.6.2021

Peripheral Artery Disease (PAD) - Severe Limb Ischemia

 

Peripheral Artery Disease

Emile R. Mohler, Michael R. Jaff

John Wiley & Sons, 13-Jul-2017 - Medical - 208 pages

A comprehensive, quick-reference guide to the diagnosis and management of peripheral artery disease for non-specialists

With an aging population subject to an increasing number of health risks, peripheral artery disease (PAD) is on the rise throughout the world. Because of PAD's direct links to heart attack and stroke, it is critical that internists, surgeons, cardiologists, radiologists, gerontologists, GPs, and family practitioners know how to recognize it and make the best treatment recommendations for their patients. This book provides all the expert, practical information and guidance they need to do just that.

Edited by two thought leaders in PAD diagnosis and treatment, and comprising chapters written by subject matter experts, Peripheral Artery Disease, Second Edition provides clinicians with guidance on how to diagnose and treat one of the most under-diagnosed conditions affecting millions of patients. This updated and revised edition of the popular guide distills the complexities of PAD into clear, actionable advice for busy medical practitioners, providing them with the information they need—when they need it.

Provides clinicians with essential information for recognizing and treating this under-diagnosed condition that affects millions of patients

Distills the complexities of PAD, from diagnosis to traditional and emerging treatment options, into clear, actionable advice for clinicians

Covers PAD epidemiology, office examination, imaging, laboratory evaluation, medical therapy, surgical interventions, endovascular treatments, and much more

Reflects the latest PAD Guidelines and Performance Measures established by leading specialty societies

Features contributions from internists and surgeons, all recognized experts in PAD

Peripheral Artery Disease, Second Edition is an important working reference for internists, cardiologists, radiologists, and surgeons, as well as fellows and residents in those fields.

https://books.google.co.in/books?id=3uEsDwAAQBAJ

LOWER EXTREMITY MANIFESTATIONS OF PERIPHERAL ARTERY DISEASE: THE PATHOPHYSIOLOGIC AND FUNCTIONAL IMPLICATIONS OF LEG ISCHEMIA

Circ Res. Author manuscript; available in PMC 2016 Apr 24.Published in final edited form as:Circ Res. 2015 Apr 24; 116(9): 1540–1550.  doi: 10.1161/CIRCRESAHA.114.303517

PMCID: PMC4410164NIHMSID: NIHMS676651PMID: 25908727

Mary McGrae McDermott, MD

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410164/

Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review

Jeffrey I. Weitz, John Byrne, G. Patrick Clagett, Michael E. Farkouh, 

Originally published1 Dec 1996https://doi.org/10.1161/01.CIR.94.11.3026Circulation. 1996;94:3026–3049

https://www.ahajournals.org/doi/full/10.1161/01.cir.94.11.3026

What is critical limb ischemia?

Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD, but less common than claudication. PAD is caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.

CLI is a chronic condition that results in severe pain in the feet or toes, even while resting. Complications of poor circulation can include sores and wounds that won't heal in the legs and feet. Left untreated, the complications of CLI will result in amputation of the affected limb.

Symptoms of critical limb ischemia

The most prominent features of critical limb ischemia are called ischemic rest pain — severe pain in the legs and feet while a person is not moving, or non-healing sores on the feet or legs. Other symptoms include:

Pain or numbness in the feet

Shiny, smooth, dry skin of the legs or feet

Thickening of the toenails

Absent or diminished pulse in the legs or feet

Open sores, skin infections or ulcers that will not heal

Dry gangrene (dry, black skin) of the legs or feet

https://health.ucdavis.edu/vascular/diseases/cli.html

Critical limb ischemia: current challenges and future prospects

Vasc Health Risk Manag. 2018; 14: 63–74. Published online 2018 Apr 26. doi: 10.2147/VHRM.S125065

PMCID: PMC5927064PMID: 29731636

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927064/

Dyslipidemia

Total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides and lipoprotein(s) are risk factors for development and progression of PAD.24 The use of statins in PAD patients is recommended. It is well documented that low levels of LDL-C reduce cardiovascular events (myocardial infarction, cerebrovascular events), and the goal in all patients with PAD is LDL-C <70 mg/dL.

Hypertension

Guidelines suggest a close control of blood pressure with values <140/90 mmHg in all patients and <130/80 mmHg in diabetic patients or patients with proteinuria. All drugs that are effective in lowering blood pressure can be used: thiazide diuretics, angiotensin-converting enzymes (ACEs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs) and beta-adrenergic blockers. In diabetic patients, ACE and ARB are considered as the first-line treatment.

https://en.wikipedia.org/wiki/Chronic_limb_threatening_ischemia

Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence

European Heart Journal, Volume 36, Issue 15, 14 April 2015, Pages 932–938, https://doi.org/10.1093/eurheartj/ehv006

https://academic.oup.com/eurheartj/article/36/15/932/2293203

Lower limb ischaemia

EBM Guidelines

7.7.2020

Palpation for foot pulses

First-line examination. The arteries to palpate are the dorsalis pedis artery and the posterior tibial artery.

Oedema will hamper the palpation.

The examiner’s own capillary pulse may interfere with the palpation.

If both the dorsalis pedis artery and the posterior tibial artery can definitely be palpated, significant arterial stenosis is improbable. An inconclusive finding is always an indication for a Doppler study.

The efficacy of pentoxiphylline has not been established. The clinical response is either of short duration, slight or insignificant.

A selective beta-blocker may usually be used with no adverse effects, unless the patient has critical ischaemia. A beta-blocker may be indicated for the treatment of coronary heart disease or hypertension.

https://www.ebm-guidelines.com/ebmg/ltk.free?p_artikkeli=ebm00101

EXERCISE REHABILITATION FOR PERIPHERAL ARTERY DISEASE: A REVIEW

Mary M. McDermott, MD

J Cardiopulm Rehabil Prev. Author manuscript; available in PMC 2019 Mar 1.Published in final edited form as:J Cardiopulm Rehabil Prev. 2018 Mar; 38(2): 63–69.  doi: 10.1097/HCR.0000000000000343

PMCID: PMC5831500NIHMSID: NIHMS932613PMID: 29465495

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831500/

Google search  "walking exercise peripheral arterial disease"

Low-Intensity vs High-Intensity Walking Exercise and Walk Distance in Patients With Peripheral Artery Disease

Original Investigation, April 6, 2021

Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease

The LITE Randomized Clinical Trial

Mary M. McDermott, et al.

JAMA. 2021;325(13):1266-1276. doi:10.1001/jama.2021.2536

Key Points

Question  Does a low-intensity (does not induce ischemic leg symptoms) home-based walking exercise intervention improve 6-minute walk distance more than a high-intensity (induces ischemic leg symptoms) home-based walking exercise intervention and does the low-intensity intervention improve 6-minute walk distance more than a nonexercise control (weekly health educational sessions only) among patients with lower-extremity peripheral artery disease (PAD)?

Findings  Low-intensity exercise, high-intensity exercise, and nonexercise control resulted in a mean 12-month change in 6-minute walk distance of −6.4 m, 34.5 m, and −15.1 m, respectively. Low-intensity exercise was significantly less effective than high-intensity exercise and was not significantly different from the nonexercise control.

Meaning  These findings do not support the use of low-intensity walking exercise for patients with PAD.

Design, Setting, and Participants  Multicenter randomized clinical trial conducted at 4 US centers and including 305 participants. Enrollment occurred between September 25, 2015, and December 11, 2019; final follow-up was October 7, 2020.

Interventions  Participants with PAD were randomized to low-intensity walking exercise (n = 116), high-intensity walking exercise (n = 124), or nonexercise control (n = 65) for 12 months. Both exercise groups were asked to walk for exercise in an unsupervised setting 5 times per week for up to 50 minutes per session wearing an accelerometer to document exercise intensity and time. The low-intensity group walked at a pace without ischemic leg symptoms. The high-intensity group walked at a pace eliciting moderate to severe ischemic leg symptoms. Accelerometer data were viewable to a coach who telephoned participants weekly for 12 months and helped them adhere to their prescribed exercise. The nonexercise control group received weekly educational telephone calls for 12 months.

Results  

Among 305 randomized patients (mean age, 69.3 [SD, 9.5] years, 146 [47.9%] women, 181 [59.3%] Black patients), 250 (82%) completed 12-month follow-up. 

The 6-minute walk distance changed from 332.1 m at baseline to 327.5 m at 12-month follow-up in the low-intensity exercise group (within-group mean change, −6.4 m [95% CI, −21.5 to 8.8 m]; P = .34) 

From 338.1 m to 371.2 m in the high-intensity exercise group (within-group mean change, 34.5 m [95% CI, 20.1 to 48.9 m]; P < .001) and the mean change for the between-group comparison was −40.9 m (97.5% CI, −61.7 to −20.0 m; P < .001). 

The 6-minute walk distance changed from 328.1 m at baseline to 317.5 m at 12-month follow-up in the nonexercise control group (within-group mean change, −15.1 m [95% CI, −35.8 to 5.7 m]; P = .10), which was not significantly different from the change in the low-intensity exercise group (between-group mean change, 8.7 m [97.5% CI, −17.0 to 34.4 m]; P = .44).

https://jamanetwork.com/journals/jama/fullarticle/2778112

Editorial

April 12, 2022

Home-Based Walking Exercise for Peripheral Artery Disease

Mary M. McDermott, MD1,2

Author Affiliations

JAMA. 2022;327(14):1339-1340. doi:10.1001/jama.2022.2457

https://jamanetwork.com/journals/jama/article-abstract/2790952

Pentoxifylline for vascular health: a brief review of the literature 

Mark F McCarty1, James H O'Keefe2 and James J DiNicolantonio2

https://openheart.bmj.com/content/3/1/e000365

Us. 19.10.2022

Pub. 17.9.2022

Abdominal Angina

 

Abdominal Angina

Kunal Mahajan; Azeberoje Osueni; Muhammad Haseeb.

Abdominal angina is postprandial pain that occurs in mesenteric vascular occlusive disease when blood flow to the colon is unable to meet visceral demands. This is similar to intermittent claudication in peripheral vascular disease or angina pectoris in coronary artery disease. 

Atherosclerotic disease is the most common cause of abdominal angina.  In most people, it is occlusion of the superior mesenteric artery that is responsible for the abdominal symptoms.

Shortly after eating, patients with abdominal angina are unable to increase flow in the mesenteric vessels, and they develop pain.

Author Information

Last Update: May 23, 2022.

https://www.ncbi.nlm.nih.gov/books/NBK441943/

Mesenteric artery disease

https://academic.oup.com/eurheartj/article/39/9/763/4095038

https://www.bcm.edu/healthcare/specialties/cardiovascular-medicine/vascular-health/mesenteric-artery-disease

Mesenteric artery stenosis

Debabrata Mukherjee and Leslie Cho.

https://www.ncbi.nlm.nih.gov/books/NBK27423/

Chronic Mesenteric Ischemia: Diagnosis and Treatment

Eric J. Hohenwalter, M.D.1

Semin Intervent Radiol. 2009 Dec; 26(4): 345–351.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036470/

Mesenteric Artery Ischemia

Alin Gragossian; Maxim E. Shaydakov; Patrick Dacquel.

Author Information

Last Update: May 9, 2022.

https://www.ncbi.nlm.nih.gov/books/NBK513354/

Chronic Mesenteric Ischemia

Ronak Patel; Abdul Waheed; Michael Costanza.

Author Information

Last Update: July 12, 2022.

Mesenteric ischemia is a manifestation of peripheral vascular disease in which the blood supply fails to meet the metabolic demands of visceral organs.

Mesenteric artery stenosis is relatively common, occurring in up to 10% of the population over 65 years of age. However, CMI has a very low incidence, accounting for less than 1 in 1000 hospital admissions for abdominal pain. Patients are typically between the ages of 50 and 70 years of age, with a strong female predominance, and have other coexisting manifestations of atherosclerotic disease.

Indications for Surgery

Signs of peritonitis on physical exam

Massive lower GI hemorrhage

Ongoing signs of abdominal pain, fever, or  sepsis

Symptoms that have persisted for more than 14 to 21 days

Chronic malabsorption leading to protein-losing colopathy

Colonoscopic evidence of segmental colitis with frank ulceration

Presence of an ischemic stricture and abdominal symptoms

https://www.ncbi.nlm.nih.gov/books/NBK430748/

Immunotherapy

Immunotherapy to Treat Cancer

Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system.

Immunotherapy is a type of biological therapy. Biological therapy is a type of treatment that uses substances made from living organisms to treat cancer.

2019

https://www.cancer.gov/about-cancer/treatment/types/immunotherapy

Chemotherapy and immunotherapy (atezolizumab).

Chemotherapy

In women with metastatic breast cancer that is hormone receptor negative, has not responded to hormone therapy, has spread to other organs or has caused symptoms, treatment may include:

Chemotherapy with one or more drugs.

Chemotherapy and immunotherapy

In women with metastatic breast cancer that is hormone receptor negative and HER2 negative, treatment may include:

Chemotherapy and immunotherapy (atezolizumab).

https://www.cancer.gov/types/breast/patient/breast-treatment-pdq#_707

https://onlinelearning.hms.harvard.edu/hmx/immunity/

https://www.allergy.org.au/patients/immunodeficiencies/covid-19-and-immunodeficiency

https://www.dw.com/en/the-immune-systems-fight-against-the-coronavirus/a-53048894

https://www.frontiersin.org/subjects/coronavirus


The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China
Wen Zhang, Yan Zhao, [...], and Shuyang Zhang
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102614/

ud. 17.9.2022

pub. 13.4.2020

Stents - Different Varieties

 September 12, 2022

Optimed’s Tentos 4-F Stent System Launched in Europe

    

September 12, 2022—Optimed,  Germany, announced the launch of the Tentos 4-F self-expanding stent system for the treatment of superficial femoral and infrapopliteal arteries. It is now commercially available. According to the company, the Tentos stent is offered in diameters of 3 to 8 mm and is compatible with 0.018-inch guidewires. The delivery system features a low crossing profile and is compatible with all 4-F sheaths. The Tentos stent is designed with thinner struts and shorter stent rings and provides tighter stent wall apposition compared to conventional superficial femoral artery stents. The Tentos system also has enhanced vessel coverage, conformability, and visibility compared to Optimed’s current 4-F stent system. 

https://evtoday.com/news/optimeds-tentos-4-f-stent-system-launched-in-europe-and-other-ce-mark-countries

Corona Disease 19 - Covid 19 - Treatment - Research Papers and News Summaries

Long Covid

Gastrointestinal sequelae 90 days after discharge for COVID-19

The Lancet, VOLUME 6, ISSUE 5, P344-346, MAY 01, 2021

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00076-5/fulltext

COVID-19 infection causing residual gastrointestinal 

symptoms – A single UK Centre Case Studies

Clinical Medicine 2022, Vol 22 No 2 March 2022

https://www.rcpjournals.org/content/clinmedicine/early/2022/02/01/clinmed.2021-0522.full-text.pdf

Long-term complications of COVID-19

Amar D. Desai,* Michael Lavelle,* Brian C. Boursiquot and Elaine Y. Wan

21 DEC 2021https://doi.org/10.1152/ajpcell.00375.2021

American Journal of Physiology-Cell PhysiologyVol. 322, No. 1

https://journals.physiology.org/doi/full/10.1152/ajpcell.00375.2021

Google Search Terms:  Research Cure for Covid

Covid Treatment Guidelines
https://covid19treatmentguidelines.nih.gov/introduction/


Covid 19 Therapeutics Tracker
https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker

About Solidarity Clinical Trials - WHO
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

Weaning from Mechanical Ventilator

https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/critical-care-medicine/difficulty-weaning-from-mechanical-ventilation-failure-to-wean-respiratory-failure-ventilator-dependence/

14 Dec 2020

E-dimer

https://journals.lww.com/md-journal/Fulltext/2020/07310/D_dimer_surge_and_coagulation_disorders_in.119.aspx

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439969/#:~:text=In%20conclusion%20higher%20admission%20D,among%20patients%20with%20COVID%2D19.

https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-020-00466-z

15  May update



May 14, 2020

NIH begins clinical trial of hydroxychloroquine and azithromycin to treat COVID-19
Study enrolling adults with mild to moderate COVID-19 in the United States.
https://www.nih.gov/news-events/news-releases/nih-begins-clinical-trial-hydroxychloroquine-azithromycin-treat-covid-19

14.05.2020
WHO to study Madagascar's drug to treat COVID-19
The World Health Organization (WHO) on Thursday said that it is in touch with Madagascar over its herbal drink Covid Organics (CVO) -- believed to cure coronavirus or COVID-19 patients.
https://www.aa.com.tr/en/africa/who-to-study-madagascars-drug-to-treat-covid-19-/1840971

13 May 2020

By mid-April, the Food and Drug Administration website had listed 72 active Covid drug trials. So far, only one drug, remdesivir, has shown promise in a major, randomized control trial to lessen the recovery time of Covid patients.

On April 17,  co-authors from institutions around the world published a paper detailing test of 12,000 drugs and identified 30 that appear to stop the virus from destroying human cells  on the preprint server bioRxiv.org. (The paper is currently being peer-reviewed for publication in a journal.) Out of the 30,  four have already been clinically tested for other uses. This helps others to plan clinical trials.
https://www.nytimes.com/2020/05/13/magazine/can-team-science-yield-a-covid-19-treatment.html




12 May 2020
COVID-19: 3-drug combo treatment may be successful
A phase II clinical trial has found that a combination of three drugs — interferon beta-1b, lopinavir-ritonavir, and ribavirin — plus standard care is successful in treating mild-to-moderate cases of COVID-19.

The results of a phase II trial suggest that a combination of three drugs may safely treat COVID-19.
This three-drug combination also shortens the duration of viral shedding — that is, the period during which the virus is detectable in a person’s body and transmissible to others. (Published in Lancet May 2020)

https://www.medicalnewstoday.com/articles/covid-19-3-drug-combo-treatment-may-be-successful

12 May
The World Health Organization said  that some treatments appear to be limiting the severity or length of the COVID-19 disease. It is a positive development.
In April,  WHO  said that there were 83 coronavirus vaccines in development globally, with six candidates -- half of them in China -- already in human trials.
https://www.livemint.com/news/world/who-says-some-treatments-appear-to-be-limiting-severity-of-coronavirus-11589282059930.html


9 May 2020

Anti-malaria drug hydroxychloroquine fails another test as a Covid-19 treatment.

Hydroxychloroquine is the only drug approved for treating hospitalised Covid-19 patients in India, where it is given in combination with the antibiotic azithromycin.

An observational study published in the New England Journal of Medicine (NEJM) concluded that the use of hydroxycholoquine neither lessened the need for patients requiring breathing assistance nor the risk of death.  1,376 consecutive patients in the emergency room with Covid-19 symptoms in the New York-Presbyterian Hospital and Columbia University Irving Medical Center in New York City were given the medicine.


Randomised-control trial evidence in larger numbers is needed and there is one , such multi-country solidarity trial being conducted by World Health Organization.  India is also participating in the solidarity trial.

Hydroxychloroquine is the only drug approved for treating hospitalised Covid-19 patients in India, where it is given in combination with the antibiotic azithromycin. It is also being given to health care workers and people at risk of exposure as a prophylaxis for Covid-19,

A small study in Brazil  was suspended after researchers found that high doses are required to fight Covid and the high does led to irregular heartbeats (heart arrhythmia).
https://www.hindustantimes.com/india-news/anti-malaria-drug-fails-another-test-as-a-covid-19-treatment-says-study/story-IadOtW6iRHIf7LMCA6AvSN.html

updated 4.4.2022, 13.12.2020.

Thyroid Problems and Diseases

http://www.drug2day.com/index.php/drug/display/21558


India Medicine Prices


Brand
Company

ELTROXIN
GSK

PROLOID
(PARKE DAVIS) PFIZER




ROXIN
ZYDUS CADILA



THYROCHEK
MANKIND


THYRONORM
KNOLL (ABBOTT)


THYROUP
LUPIN

THYROWIN
PIRAMAL H.C

THYROX
MACLEODS

Adv Ther. 2019; 36(Suppl 2): 30–46.

Published online 2019 Sep 4. doi: 10.1007/s12325-019-01078-2

PMCID: PMC6822824

PMID: 31485977

Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient’s Lifetime

Leonidas H. Duntascorresponding author1 and Jacqueline Jonklaas2

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822824/

Effects of Altering Levothyroxine Dose on Energy Expenditure and Body Composition in Subjects Treated With LT4 

Mary H Samuels, Irina Kolobova, Meike Niederhausen, Jonathan Q Purnell, Kathryn G Schuff

The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 11, November 2018, Pages 4163–4175, https://doi.org/10.1210/jc.2018-01203

No effect was found in the study.

https://academic.oup.com/jcem/article/103/11/4163/5078436

Does Hypothyroidism Affect Gastrointestinal Motility?

Hindawi

January 2009, Gastroenterology Research and Practice 2009(1687-6121):529802

DOI:10.1155/2009/529802

https://www.researchgate.net/publication/41910901_Does_Hypothyroidism_Affect_Gastrointestinal_Motility

ud. 4.4.2022, 30.3.2022

Pub 24.1.2016